2016 yellow fever outbreak

2016 yellow fever outbreak
Name	2016 yellow fever outbreak
Date	2016
Place	Angola; Democratic Republic of the Congo; Kenya; Uganda; China (imported)
Deaths	estimates variable

2016 yellow fever outbreak The 2016 yellow fever outbreak in Angola and the Democratic Republic of the Congo was a major epidemic that prompted international emergency response and vaccine campaigns. The event drew attention from World Health Organization, United Nations, Centers for Disease Control and Prevention, Médecins Sans Frontières, and national health ministries such as Ministry of Health (Angola) and Ministry of Public Health (Democratic Republic of the Congo). The outbreak influenced global vaccine stockpile policy involving Gavi, the Vaccine Alliance, Pan American Health Organization, and manufacturers like Bio-Manguinhos and Bavarian Nordic.

Background

Urban yellow fever has historical precedence in port cities linked to the Transatlantic slave trade, International Health Regulations (2005), and nineteenth-century epidemics such as the Yellow fever epidemic of 1878. Yellow fever virus is a flavivirus studied alongside dengue virus, Zika virus, and West Nile virus within research at institutions like Pasteur Institute, Rockefeller Foundation, and National Institutes of Health. Prior to 2016, notable outbreaks occurred in Angola and other African nations, prompting surveillance activities by Africa Centres for Disease Control and Prevention and routine immunization programs coordinated with World Health Organization and Gavi, the Vaccine Alliance.

Outbreak timeline

Cases emerged in early 2016 with suspected infections reported to provincial health authorities such as Ministry of Health (Angola), who notified World Health Organization under the International Health Regulations (2005). By mid-2016 clusters increased in Luanda and surrounding provinces, triggering emergency vaccine requests to the International Coordinating Group on Vaccine Provision. In May and June 2016, importation of cases to Kinshasa and cities in the Democratic Republic of the Congo escalated responses from Ministry of Public Health (Democratic Republic of the Congo) and partners including United Nations Children's Fund and Médecins Sans Frontières. The outbreak later produced exported cases to China and consultations with agencies such as Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control.

Geographic spread and affected populations

Initial epicenters were urban districts of Luanda attracting internal migrants, expatriate communities, and travelers linked to ports and air routes serving Quatro de Fevereiro Airport and regional hubs. Secondary transmission occurred in Huambo, Benguela, and other Angolan provinces before spread across borders to the Democratic Republic of the Congo with clusters in Kinshasa and provinces connected by riverine transport along the Congo River. Affected populations included residents of informal settlements, workers in transport sectors, and unvaccinated cohorts targeted by child immunization programs under Expanded Programme on Immunization (WHO). International concern rose when travelers carrying infections arrived in China and prompted screening at points of entry overseen by agencies like World Health Organization and national public health institutes.

Public health response and vaccination campaigns

Responses combined mass vaccination campaigns organized by Ministry of Health (Angola), Ministry of Public Health (Democratic Republic of the Congo), World Health Organization, Gavi, the Vaccine Alliance, and the International Coordinating Group on Vaccine Provision. Emergency strategies included fractional dosing advised by specialists from Centers for Disease Control and Prevention, Johns Hopkins Bloomberg School of Public Health, and London School of Hygiene & Tropical Medicine to extend supplies produced by manufacturers such as Bio-Manguinhos and supported by procurement via Pan American Health Organization. Vector control operations coordinated with municipal authorities engaged teams from Médecins Sans Frontières and non-governmental groups, while surveillance enhancements involved laboratories at Pasteur Institute and reference centers linked to Global Outbreak Alert and Response Network.

Epidemiology and case statistics

Surveillance reports compiled by World Health Organization and national ministries documented thousands of suspected cases and several hundred laboratory-confirmed infections, with case-fatality ratios reported variably across provinces and timeframes. Epidemiological analyses published by researchers affiliated with Centers for Disease Control and Prevention, London School of Hygiene & Tropical Medicine, and University of Oxford examined transmission dynamics, attack rates in urban settings like Luanda, and the impact of delayed routine immunization by programs such as Expanded Programme on Immunization (WHO). Data influenced modeling work at institutions like Imperial College London and projections used in policy discussions at Gavi, the Vaccine Alliance.

Causes and vector control measures

The outbreak was driven by yellow fever virus transmission by Aedes mosquitoes, primarily Aedes aegypti, sharing ecology with vectors involved in dengue fever and Zika virus transmission studied at centers like Pasteur Institute and Rockefeller Foundation. Contributing factors included urbanization patterns in Luanda, gaps in routine immunization overseen historically by Expanded Programme on Immunization (WHO), and international travel via hubs such as Quatro de Fevereiro Airport. Vector control measures combined larval source reduction, insecticide spraying coordinated with municipal services, and community mobilization supported by United Nations Children's Fund and World Health Organization while entomological surveillance drew on expertise from London School of Hygiene & Tropical Medicine and national public health laboratories.

Impact and aftermath

The outbreak prompted revisions to global stockpile policies at World Health Organization and investments by Gavi, the Vaccine Alliance in vaccine manufacturing capacity with partners such as Bio-Manguinhos and emergency frameworks managed by the International Coordinating Group on Vaccine Provision. Long-term impacts included strengthened surveillance systems linked to Africa Centres for Disease Control and Prevention, enhanced routine immunization under Expanded Programme on Immunization (WHO), and research initiatives at National Institutes of Health and Pasteur Institute addressing vaccine strategies and vector ecology. The event reinforced international collaboration involving World Health Organization, United Nations, Centers for Disease Control and Prevention, and non-governmental organizations such as Médecins Sans Frontières to prevent future urban yellow fever epidemics.

Category:Yellow fever outbreaks